Loading clinical trials...
Loading clinical trials...
The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
NCT07409181 · Systemic Lupus Erythematosus
NCT07043153 · Systemic Lupus Erythematosus Disease
NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more
NCT07558850 · Rheumatoid Arthritis, Dermatomyositis, and more
NCT07526350 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, and more
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui
Peking University People's Hospital
Beijing, Beijing Municipality
Peking University third hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions